During the past decade, Synexus Polska Sp. z o.o. Oddzial w Gdyni conducted 36 clinical trials. In the 10-year time frame, 36 clinical trials started and 33 clinical trials were completed, i.e. on average, 91.7% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 20 clinical trials were completed. i.e. 133.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Synexus Polska Sp. z o.o. Oddzial w Gdyni" #1 sponsor was "Pfizer" with 13 trials, followed by "Amgen" with 4 trials sponsored, "Boehringer Ingelheim" with 4 trials sponsored, "Incyte Corporation" with 3 trials sponsored and "Bristol-Myers Squibb" with 3 trials sponsored. Other sponsors include 15 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Synexus Polska Sp. z o.o. Oddzial w Gdyni" #1 collaborator was "Brigham and Women's Hospital" with 1 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 1 trials as a collaborator, "Quintiles, Inc." with 1 trials as a collaborator, "Shire" with 1 trials as a collaborator and "Teva Pharmaceutical Industries, Ltd." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Synexus Polska Sp. z o.o. Oddzial w Gdyni" are "Psoriasis" (5 trials), "Rheumatoid Arthritis" (5 trials), "Crohn's Disease" (3 trials), "Cardiovascular Disease" (2 trials) and "Chronic Rhinosinusitis" (2 trials). Many other conditions were trialed in "Synexus Polska Sp. z o.o. Oddzial w Gdyni" in a lesser frequency.

Most popular intervention types in "Synexus Polska Sp. z o.o. Oddzial w Gdyni" are "Drug" (41 trials), "Biological" (6 trials), "Other" (4 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (22 trials), "Apremilast 20mg" (2 trials), "Apremilast 30mg" (2 trials), "BI 695501" (2 trials) and "BMS-986165" (2 trials). Other intervention names were less common.

The vast majority of trials in "Synexus Polska Sp. z o.o. Oddzial w Gdyni" are 45 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Synexus Polska Sp. z o.o. Oddzial w Gdyni". undefined are not yet recruiting, 4 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 32 completed trials in Synexus Polska Sp. z o.o. Oddzial w Gdyni, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Synexus Polska Sp. z o.o. Oddzial w Gdyni, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 36 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".